5 Sciences of Weight Management and The Anti-Obesity Drug Revelation -written by Poonam Chanchlani (BCA, Data Science)

A groundbreaking experimental anti-obesity drug has shown remarkable potential by effectively curbing appetite and normalizing blood glucose levels, all without the common side effects of nausea and vomiting associated with current weight-loss and diabetes medications.

 

Developed as a peptide treatment, this innovative drug not only reduces food intake but also boosts calorie burn rates, leading to consistent and significant weight loss in lab animals. Spearheaded by Robert Doyle, Dean’s Professor of Chemistry, and Christian Roth, M.D. of Seattle Children’s Research Institute, the project's findings were unveiled at the American Chemical Society's (ACS) spring meeting in March. The event featured over 10,000 presentations, offering the global science community an early glimpse into groundbreaking research.

 

Unlike gastric bypass surgeries that reset the endocrine system to induce weight loss, this drug seeks to replicate similar benefits without the need for invasive procedures.  Doyle states, "With this new drug treatment, we aim to chemically replicate the benefits of surgery without patients having to undergo surgery."

 

Current anti-obesity medications often fail to deliver consistent long-term weight loss, often accompanied by substantial side effects leading many patients to discontinue usage. Doyle highlights the need for a universally effective solution, explaining, "This new treatment, which could be injected in humans once a week, would be a way to lose a given percent of your weight and not feel sick while doing it."

 

The researchers synthesized the peptide drug GEP44, comprising 44 amino acids targeting multiple weight-loss and glucoregulatory receptor pathways simultaneously. Administering the drug led to a staggering 80% reduction in food consumption in obese rats and an average weight loss of 12% within a 16-day study. Crucially, the drug did not induce vomiting in shrews, a mammalian model. The team has filed for patents and intends to progress to primate testing.

 

The groundbreaking research received support from the Congressionally Directed Medical Research Programs of the U.S. Department of Defense, driven by the relevance of tackling weight-related type 2 diabetes, particularly among veterans.